Search Results - "Pechonkina, Alena"

Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years by Ishiguro, Naoki, Tanaka, Yoshiya, Matsubara, Tsukasa, Atsumi, Tatsuya, Amano, Koichi, Sugiyama, Eiji, Yamaoka, Kunihiro, Winthrop, Kevin, Kivitz, Alan, Burmester, Gerd R, Gottenberg, Jacques-Eric, Genovese, Mark C, Matzkies, Franziska, Guo, Ying, Jiang, Deyuan, Bartok, Beatrix, Pechonkina, Alena, Kondo, Akira, Besuyen, Robin, Takeuchi, Tsutomu

“…Characterize safety of the Janus kinase-1 preferential inhibitor filgotinib (FIL) in Japanese patients with moderately to severely active rheumatoid arthritis…”
Get full text

Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3) by Atsumi, Tatsuya, Tanaka, Yoshiya, Matsubara, Tsukasa, Amano, Koichi, Ishiguro, Naoki, Sugiyama, Eiji, Yamaoka, Kunihiro, Westhovens, René, Ching, Daniel W T, Messina, Osvaldo Daniel, Burmester, Gerd R, Genovese, Mark, Bartok, Beatrix, Pechonkina, Alena, Kondo, Akira, Yin, Zhaoyu, Gong, Qi, Tasset, Chantal, Takeuchi, Tsutomu

“…ABSTRACT Objectives To evaluate the long-term safety and efficacy of filgotinib (FIL) for Japanese patients with rheumatoid arthritis (RA) and limited/no prior…”
Get full text

Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1) by Tanaka, Yoshiya, Matsubara, Tsukasa, Atsumi, Tatsuya, Amano, Koichi, Ishiguro, Naoki, Sugiyama, Eiji, Yamaoka, Kunihiro, Combe, Bernard G, Kivitz, Alan J, Bae, Sang-Cheol, Keystone, Edward C, Nash, Peter, Matzkies, Franziska, Bartok, Beatrix, Pechonkina, Alena, Kondo, Akira, Ye, Lei, Guo, Ying, Tasset, Chantal, Sundy, John S, Takeuchi, Tsutomu

“…Evaluate the efficacy and safety of the Janus kinase-1 inhibitor filgotinib in Japanese patients with rheumatoid arthritis (RA) and inadequate response to…”
Get full text

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials by Tanaka, Yoshiya, Atsumi, Tatsuya, Aletaha, Daniel, Bartok, Beatrix, Pechonkina, Alena, Han, Ling, Emoto, Kahaku, Kano, Shungo, Rajendran, Vijay, Takeuchi, Tsutomu

“…Introduction We conducted a post hoc analysis of efficacy and safety of filgotinib stratified by estimated radiographic progression rate before baseline (BL)…”
Get full text

Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2) by Takeuchi, Tsutomu, Matsubara, Tsukasa, Atsumi, Tatsuya, Amano, Koichi, Ishiguro, Naoki, Sugiyama, Eiji, Yamaoka, Kunihiro, Genovese, Mark C., Kalunian, Kenneth, Walker, David, Gottenberg, Jacques-Eric, Vlam, Kurt de, Bartok, Beatrix, Pechonkina, Alena, Kondo, Akira, Gao, Jie, Guo, Ying, Tasset, Chantal, Sundy, John S., Tanaka, Yoshiya

“…To evaluate efficacy and safety of filgotinib in Japanese RA patients who have failed or were intolerant to one or more biologic disease-modifying…”
Get full text

Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3) by Atsumi, Tatsuya, Tanaka, Yoshiya, Matsubara, Tsukasa, Amano, Koichi, Ishiguro, Naoki, Sugiyama, Eiji, Yamaoka, Kunihiro, Westhovens, René, Ching, Daniel W T, Messina, Osvaldo Daniel, Burmester, Gerd R, Bartok, Beatrix, Pechonkina, Alena, Kondo, Akira, Yin, Zhaoyu, Guo, Ying, Tasset, Chantal, Sundy, John S, Takeuchi, Tsutomu

“…To evaluate the efficacy and safety of filgotinib for Japanese patients with rheumatoid arthritis (RA) and limited or no prior methotrexate (MTX) exposure…”
Get full text

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study by Combe, Bernard G., Tanaka, Yoshiya, Buch, Maya H., Nash, Peter, Burmester, Gerd R., Kivitz, Alan J., Bartok, Beatrix, Pechonkina, Alena, Xia, Katrina, Emoto, Kahaku, Kano, Shungo, Hendrikx, Thijs K., Landewé, Robert B. M., Aletaha, Daniel

“…Introduction This exploratory analysis of FINCH 1 (NCT02889796) examined filgotinib (FIL) efficacy and safety in a subgroup of patients with rheumatoid…”
Get full text

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study by Combe, Bernard G., Tanaka, Yoshiya, Buch, Maya H., Nash, Peter, Burmester, Gerd R., Kivitz, Alan J., Bartok, Beatrix, Pechonkina, Alena, Xia, Katrina, Emoto, Kahaku, Kano, Shungo, Hendrikx, Thijs K., Landewé, Robert B. M., Aletaha, Daniel

Get full text

CLINICAL OUTCOMES IN REAL-WORLD PATIENTS RECEIVING THE XIENCE V® EVEROLIMUS-ELUTING STENT PRESENTING WITH CHRONIC KIDNEY DISEASE: ONE-YEAR RESULTS FROM THE XIENCE V USA STUDY by Gruberg, Luis, Jeremias, Allen, Rutledge, David R, Mao, Vivian W, Zhao, Weiying, Pechonkina, Alena V, Wang, Jin, Wilburn, Olivia, Sudhir, Krishnankutty, Krucoff, Mitchell W, Hermiller, James B

Get full text

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren's syndrome: a randomized, phase 2, double-blind, placebo-controlled study by Price, Elizabeth, Bombardieri, Michele, Kivitz, Alan, Matzkies, Franziska, Gurtovaya, Oksana, Pechonkina, Alena, Jiang, Wendy, Downie, Bryan, Mathur, Anubhav, Mozaffarian, Afsaneh, Mozaffarian, Neelufar, Gottenberg, J Eric

“…The aim of this study was to characterize the safety and efficacy of filgotinib, lanraplenib and tirabrutinib in patients with active SS. This multicentre,…”
Get full text

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study by Werth, Victoria P, Fleischmann, Roy, Robern, Michael, Touma, Zahi, Tiamiyu, Iyabode, Gurtovaya, Oksana, Pechonkina, Alena, Mozaffarian, Afsaneh, Downie, Bryan, Matzkies, Franziska, Wallace, Daniel

“…Abstract Objectives To explore the safety and efficacy of filgotinib (FIL), a Janus kinase 1 inhibitor, and lanraplenib (LANRA), a spleen kinase inhibitor, in…”
Get full text

P199 Clinical outcomes up to week 48 of ongoing filgotinib rheumatoid arthritis long-term extension trial of biologic disease modifying anti-rheumatic drugs inadequate responders initially on filgotinib or placebo in a Phase 3 trial by Buch, Maya, Takeuchi, Tsutomu, Rajendran, Vijay, Gottenberg, Jacques-Eric, Pechonkina, Alena, Tan, YingMeei, Gong, Qi, Van Beneden, Katrien, Caporali, Roberto

“…Abstract Background/Aims The preferential Janus kinase-1 inhibitor filgotinib (FIL) is approved to treat RA in Europe. We assessed FIL efficacy/safety in…”
Get full text

OA29 Clinical outcomes up to week 48 of filgotinib treatment in an ongoing long-term extension trial of RA patients with inadequate response to methotrexate initially treated with filgotinib or adalimumab during the Phase 3 Parent Trial by Combe, Bernard, Tanaka, Yoshiya, Emery, Paul, Pechonkina, Alena, Kuo, Albert, Gong, Qi, Van Beneden, Katrien, Rajendran, Vijay, Schulze-Koops, Hendrik

“…Abstract Background/Aims The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in…”
Get full text

Safety and efficacy of filgotinib in Japanese patients with rheumatoid arthritis: Week 156 interim results in FINCH 4 by Tanaka, Yoshiya, Matsubara, Tsukasa, Atsumi, Tatsuya, Amano, Koichi, Ishiguro, Naoki, Hirata, Shintaro, Yamaoka, Kunihiro, Combe, Bernard G, Nash, Peter, Genovese, Mark, Pechonkina, Alena, Liu, Jie, Kondo, Akira, Fukada, Haruhiko, Leonardis, Francesco De, Takeuchi, Tsutomu

“…Abstract Objectives: To describe safety and efficacy of filgotinib 200 or 100 mg (FIL200/FIL100) in Japanese patients with rheumatoid arthritis in a long-term…”
Get full text

Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results by Tanaka, Yoshiya, Matsubara, Tsukasa, Atsumi, Tatsuya, Amano, Koichi, Ishiguro, Naoki, Sugiyama, Eiji, Yamaoka, Kunihiro, Combe, Bernard G, Kivitz, Alan J, Bae, Sang-Cheol, Keystone, Edward C, Nash, Peter, Genovese, Mark, Matzkies, Franziska, Bartok, Beatrix, Pechonkina, Alena, Kondo, Akira, Ye, Lei, Gong, Qi, Tasset, Chantal, Takeuchi, Tsutomu

“…ABSTRACT Objectives To present safety and efficacy of the JAK1 preferential inhibitor filgotinib in Japanese patients with prior inadequate response (IR) to…”
Get full text

Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2) by Takeuchi, Tsutomu, Matsubara, Tsukasa, Atsumi, Tatsuya, Amano, Koichi, Ishiguro, Naoki, Sugiyama, Eiji, Yamaoka, Kunihiro, Genovese, Mark C, Kalunian, Kenneth, Walker, David, Gottenberg, Jacques-Eric, de Vlam, Kurt, Bartok, Beatrix, Pechonkina, Alena, Kondo, Akira, Gao, Jie, Guo, Ying, Tasset, Chantal, Sundy, John S, Tanaka, Yoshiya

“…To evaluate efficacy and safety of filgotinib in Japanese RA patients who have failed or were intolerant to one or more biologic disease-modifying…”
Get full text